SCHEMBL1961871

SCHEMBL1961871

Cc1ccccc1Cc1nn(C(C)(C)C)c2ncnc(N)c12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 17/20 0.73
ABL1 P00519 8/20 0.73
RIPK2 O43353 4/20 0.73
FYN P06241 4/20 0.73
PRKD3 O94806 4/20 0.73
PRKD2 Q9BZL6 4/20 0.73
CSK P41240 3/20 0.73
PRKACA P17612 3/20 0.73
CSNK1A1 P48729 3/20 0.73
MAPK14 Q16539 3/20 0.73
MAPK8 P45983 3/20 0.73
PRKD1 Q15139 3/20 0.73
CDK2 P24941 2/20 0.73
CAMK2A Q9UQM7 2/20 0.73
CSNK1E P49674 1/20 0.73
CDK12 Q9NYV4 1/20 0.73
AKT1 P31749 1/20 0.60
CSNK1D P48730 3/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12551741 0.91 SRC (0.71) SRCABL1RIPK2FYNPRKD3
SCHEMBL12551799 0.88 SRC (0.73) SRCABL1RIPK2FYNPRKD3
SCHEMBL1962448 0.87 SRC (0.72) SRCABL1RIPK2FYNPRKD3
SCHEMBL12551804 0.87 SRC (0.72) SRCABL1RIPK2FYNPRKD3
SCHEMBL30250446 0.87 SRC (0.72) SRCABL1RIPK2FYNPRKD3
SCHEMBL408505 0.87 SRC (0.72) SRCABL1RIPK2FYNPRKD3
SCHEMBL13019708 0.86 SRC (0.74) SRCABL1RIPK2FYNPRKD3
SCHEMBL20812894 0.86 SRC (0.61) SRCABL1RIPK2FYNPRKD3
SCHEMBL22930423 0.86 SRC (0.61) SRCABL1RIPK2FYNPRKD3
SCHEMBL1960668 0.86 SRC (0.61) SRCABL1RIPK2FYNPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 US disclosed
US-20230014124-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-01-19 US disclosed
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10905768-B1 Heterocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-02-02 US disclosed
US-9512125-B2 Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-12-06 US disclosed
US-9512125-B2 Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-12-06 US disclosed
US-9512125-B2 Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-12-06 US disclosed
US-20110144134-A1 Anti-Inflammatory Pyrazolopyrimndines THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-16 US disclosed
US-20110144134-A1 Anti-Inflammatory Pyrazolopyrimndines THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-16 US disclosed
US-20110144134-A1 Anti-Inflammatory Pyrazolopyrimndines THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-16 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20090124638-A1 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-14 US disclosed
US-20090124638-A1 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-14 US disclosed
US-20090124638-A1 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014124-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION CRBN, MDM2, STUB1 SRC 766/4885ABL1 1463/4885RIPK2 235/4885
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A SRC 1396/4885ABL1 3456/4885RIPK2 709/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A SRC 1396/4885ABL1 3456/4885RIPK2 709/4885
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DBN1, MYCBP, PSMG3 SRC 3905/4885ABL1 2538/4885RIPK2 2196/4885
US-20110144134-A1 Anti-Inflammatory Pyrazolopyrimndines TSLP, NLRP3, IL1B SRC 3970/4885ABL1 2987/4885RIPK2 650/4885
US-10905768-B1 Heterocyclic degronimers for target protein degradation CRBN, MDM2, STUB1 SRC 766/4885ABL1 1463/4885RIPK2 235/4885
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885ABL1 1725/4885RIPK2 2849/4885
US-20090124638-A1 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES TNF, TSLP, IL1B SRC 3920/4885ABL1 2533/4885RIPK2 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.